ESPE Abstracts

Introduction: Octreotide is recommended as a second-line treatment for patients with congenital hyperinsulinism (CHI), particularly for those who do not respond to diazoxide orsurgical treatment. While the studies on the adverse effects ofoctreotide are still scarce in large cohorts.Methods: A retrospective study was conducted on CHIpatients who were treated with octreotide in the two largestcenters in China. The study c...